120 related articles for article (PubMed ID: 8949993)
21. Use of amifostine as a chemoprotectant during high-dose chemotherapy in autologous peripheral blood stem cell transplantation.
Cronin S; Uberti JP; Ayash LJ; Raith C; Ratanatharathorn V
Bone Marrow Transplant; 2000 Dec; 26(11):1247-9. PubMed ID: 11149742
[TBL] [Abstract][Full Text] [Related]
22. Clinical use of serum TRA-1-60 as tumor marker in patients with germ cell cancer.
Lajer H; Daugaard G; Andersson AM; Skakkebaek NE
Int J Cancer; 2002 Jul; 100(2):244-6. PubMed ID: 12115576
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro.
Harstrick A; Casper J; Guba R; Wilke H; Poliwoda H; Schmoll HJ
Cancer; 1989 Mar; 63(6):1079-83. PubMed ID: 2645036
[TBL] [Abstract][Full Text] [Related]
24. Testicular function in patients with testicular cancer treated with bleomycin-etoposide-carboplatin (BEC(90)) combination chemotherapy.
Pectasides D; Pectasides M; Farmakis D; Nikolaou M; Koumpou M; Kostopoulou V; Mylonakis N
Eur Urol; 2004 Feb; 45(2):187-93. PubMed ID: 14734005
[TBL] [Abstract][Full Text] [Related]
25. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
26. Modulation of cytostatic drugs by nifedipine in two heterotransplanted human testicular-cancer cell lines differing in their sensitivity to standard agents.
Bokemeyer C; Dunn T; Harstrick A; Lerch T; Poliwoda H; Schmoll HJ
Int J Cancer; 1994 Feb; 56(3):452-6. PubMed ID: 7906255
[TBL] [Abstract][Full Text] [Related]
27. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours.
Fosså SD; Stenning SP; Gerl A; Horwich A; Clark PI; Wilkinson PM; Jones WG; Williams MV; Oliver RT; Newlands ES; Mead GM; Cullen MH; Kaye SB; Rustin GJ; Cook PA
Br J Cancer; 1999 Jul; 80(9):1392-9. PubMed ID: 10424741
[TBL] [Abstract][Full Text] [Related]
29. Protective effect of Ginkgo flavonoids, amifostine, and leuprorelin against platinum-induced ovarian impairment in rats.
Chang Z; Wang HL; Du H
Genet Mol Res; 2014 Jul; 13(3):5276-84. PubMed ID: 25078583
[TBL] [Abstract][Full Text] [Related]
30. Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicity.
Asna N; Lewy H; Ashkenazi IE; Deutsch V; Peretz H; Inbar M; Ron IG
Life Sci; 2005 Mar; 76(16):1825-34. PubMed ID: 15698860
[TBL] [Abstract][Full Text] [Related]
31. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
32. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
33. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors.
Souid AK; Dubowy RL; Blaney SM; Hershon L; Sullivan J; McLeod WD; Bernstein ML
Clin Cancer Res; 2003 Feb; 9(2):703-10. PubMed ID: 12576438
[TBL] [Abstract][Full Text] [Related]
34. Efficient carboplatin single therapy in a mouse model of human testicular nonseminomatous germ cell tumor.
Aharinejad S; Fink M; Abri H; Nedwed S; Schlag MG; Macfelda K; Abraham D; Miksovsky A; Höltl E; Höltl W
J Urol; 2002 Jan; 167(1):368-74. PubMed ID: 11743358
[TBL] [Abstract][Full Text] [Related]
35. Optimal number of chemotherapy courses in advanced nonseminomatous testicular carcinoma.
Kennedy BJ; Torkelson J; Fraley EE
Am J Clin Oncol; 1995 Dec; 18(6):463-8. PubMed ID: 8526185
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.
Pont J; Albrecht W; Postner G; Sellner F; Angel K; Höltl W
J Clin Oncol; 1996 Feb; 14(2):441-8. PubMed ID: 8636755
[TBL] [Abstract][Full Text] [Related]
37. Cisplatin-based chemotherapy for testicular cancer in a patient with spinal muscular atrophy: a case report.
Sokol DB; Hudes GR
Am J Clin Oncol; 1998 Aug; 21(4):420-1. PubMed ID: 9708647
[TBL] [Abstract][Full Text] [Related]
38. [Long-term side effects of chemotherapy for testicular cancer].
Kawai K
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1300-5. PubMed ID: 12146015
[TBL] [Abstract][Full Text] [Related]
39. Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin.
Hanigan MH; Frierson HF; Abeler VM; Kaern J; Taylor PT
Br J Cancer; 1999 Sep; 81(1):75-9. PubMed ID: 10487615
[TBL] [Abstract][Full Text] [Related]
40. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
